Europe Genotyping Market Forecast to 2028 – COVID

Europe Genotyping Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product and Services (Instruments, Reagents and Kits, Bioinformatics, and Genotyping Services), Technology [Microarrays, Capillary Electrophoresis, Sequencing, Polymerase Chain Reaction (PCR), Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof) Mass Spectrometry, and Others], Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Animal Genetics, Agricultural Biotechnology, and Others), and End User (Pharmaceutical and Biopharmaceutical Companies, Diagnostic and Research Laboratories, Academic Institutes, and Others)

Report Code : BMIRE00025969 | Region : Europe | Industry : Pharmaceuticals | Published Date : 16/Sep/2022

The genotyping market in Europe is expected to grow from US$ 6,178.64 million in 2022 to US$ 19,073.60 million by 2028. It is estimated to grow at a CAGR of 20.7% from 2022 to 2028.

According to the study, personalized medicine is the customization of medical treatment to each patient's unique traits. The method is based on scientific advances in understanding how a person's unique molecular and genetic profile influences susceptibility to diseases and predicts which medical treatments are safe and effective and which are not. Senior government officials, corporate leaders, healthcare practitioners, and the general public have embraced genomics and personalized medicine over the last decade. Genomic medicine is a fundamental component of personalized medicine, a fast-growing health care branch guided by each person's unique clinical, genetic, genomic, and environmental information.

The fundamentals of genomic and personalized medicine will require the development, standardization, and integration of several essential tools into health systems and clinical workflows as medicine embraces genomic tools that enable more precise disease prediction and treatment, such as "whole-genome" interrogation of sequence variation, transcription, proteins, and metabolites. Among the techniques available are health risk assessment, family health history, and clinical decision assistance for complex risk and predictive information. Combined with genomic data, these tools will enable a paradigm change toward a holistic strategy that will detect individual risks and guide clinical treatment and decision-making, laying the groundwork for a more informed and effective patient care approach. Genome-guided therapy, dose selection, DNA-based risk assessment for common complex diseases, and molecular signatures for cancer diagnosis and prognosis are examples of how genome information has already enabled personalized healthcare For instance, genome-guided treatment is perhaps the most well-studied effect of precision medicine on health care today. Clinicians have used genotype data as a guideline to calculate the correct warfarin dose. To assist doctors in optimizing pharmacological therapy based on genetic test results, the Clinical Pharmacogenetics Implementation Consortium produced genotype-based drug guidelines.

For individuals with breast or lung cancer, genomic analysis of tumors can help guide tailored therapeutic approaches. When precision medicine is integrated into healthcare, it can provide more accurate diagnoses, anticipate disease risk before symptoms appear, and provide individualized treatment plans that maximize safety and efficiency. For instance, in June 2022, FinnGen is a large-scale academic/industrial research collaborative in Finland that aims to collect and analyze genetic and health data from 500,000 Finnish biobank members in Finland. It's one of the first personalized medicine projects to provide new, therapeutically valuable insights while also building a world-class resource that may be used in future research.

Over 400 new disease-related loci have been discovered due to the FinnGen investigation, with the linked gene variant being enriched in the Finnish population. FinnGen has selected Olink to conduct the project's thorough proteome profiling of up to 2500 participants. These findings can be used to fuel more functional research in conjunction with high-quality proteomics, perhaps yielding novel insights into disease pathways.

Furthermore, data from individual genomes, a rapidly developing technology area, is causing a social and information revolution among customers, undoubtedly influencing healthcare decision-making. Although these and other scientific discoveries are making their way from the lab to the clinic, widespread acceptance of genomic and personalized medicine will necessitate significant changes in regulatory and reimbursement procedures and legislative privacy laws. Thus, customized health care challenges will be met and overcome with the assurance that the research behind genetic medicine is decent and that the practice of medicine that it informs is evidence-based. Over time, there has been a steady trend away from the old 'one pill fits all' strategy and toward a more individualized, patient-centered approach. Patients, health, and diseases are now treated with a more predictive, preventive, participatory, and individualized approach in medicine. This so-called P4 medicine has numerous problems and roadblocks, but it also presents numerous opportunities for improving care and therapeutic outcomes; therefore, such developments will represent a demand for personalized medicine, offering a growth curve for the market over the study period.

Europe Genotyping Market Revenue and Forecast to 2028 (US$ Million)

Europe Genotyping Market Segmentation

The Europe genotyping market is segmented by products and services, technology, application, end user, and country. Based on products and services, the market is segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment is dominating the market in 2022.

Based on technology, the market is segmented into microarrays, capillary electrophoresis, sequencing, matrix-assisted laser desorption/ionization-time of flight (Maldi-ToF) mass spectrometry, polymerase chain reaction (PCR), and others. The PCR segment is dominating the market in 2022.

Based on application, the market is segmented into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and others. The diagnostics and personalized medicine segment is dominating the market in 2022.

Based on end user, the market is segmented into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and others. The diagnostics and research laboratories segment is dominating the market in 2022.

Based on country, the market is segmented into the UK, Germany, France, Italy, Spain, and the rest of Europe. Further, Germany dominated the market in 2022.

A few key players dominating the Europe genotyping market are BioTek Instruments, Inc.; Eurofins Genomics; F. Hoffmann-La Roche Ltd.; Illumina, Inc.; Integrated DNA Technologies, Inc.; MERCK KGaA; QIAGEN; Thermo Fisher Scientific Inc; and TrimGen Corporation.

At 20.7% CAGR, the Europe Genotyping Market is speculated to be worth US$ 19,073.60 million by 2028, says The Insight Partners

According to The Insight Partners’ research, the Europe genotyping market was valued at US$ 6,178.64 million in 2022 and is expected to reach US$ 19,073.60 million by 2028, registering an annual growth rate of 20.7% from 2022 to 2028. The use of genotyping in drug development for genetic and rare diseases and rising focus on personalized medicine are the critical factors attributed to the market expansion.

Genotyping compares a DNA sequence to another sample or a reference sequence to discover variations in genetic complement. It detects single-nucleotide polymorphisms (SNPs), which are minor differences in genetic sequence within the population. The human genome has about 660 million SNPs, making them the most prevalent kind of genetic variation. They can explain features such as eye color and hereditary disorders such as cystic fibrosis and sickle cell anemia and serve as indicators for developing complicated diseases such as cancer, diabetes, and Alzheimer's. The introduction of high-throughput genotyping technologies has greatly advanced our understanding of the genetic components of complex disorders, such as T2D. Additionally, by comparing polymorphisms in two distinct populations (one healthy and one diseased), genome-wide association studies (GWAS) can uncover links between SNPs and common illness risk. GWAS can begin to untangle the molecular mechanisms underlying disease states by finding probable causative variables risk stratification. Single-celled organisms, such as bacteria, even have SNPs. SNP genotyping can discriminate between microorganism isolates and might even be accustomed to characterizing antibiotic resistance strains. SNP-based strain detection has relevance in each clinical and pharmaceutical analysis and has been used to study the spread of infectious diseases in humans. Since these conditions are difficult to identify clinically, genotyping is the backbone of diagnostic testing in the population. This rising adoption of prenatal genetic screening to examine children's chromosomal anomalies could prove to be a major driving factor. Over the last decade, next-generation sequencing (NGS) technology has enabled simultaneous testing of multiple disease genes, from targeted gene panels to exome sequencing (ES) and genomic sequencing (GS). GS is quickly becoming a practical first-stage test as costs decrease and performance improves. More and more studies show that GS can detect an unprecedented range of pathogenic abnormalities in a single laboratory. GS has the potential to provide patients with unbiased, rapid, and accurate molecular diagnostics that transcend diverse clinical indications and complex conditions. Therefore, the use in drug development for genetic and rare diseases will act as one of the key factors driving the growth of the genotyping markets.

On the contrary, high cost of equipment and shortage of skilled professionals required for genotyping process hurdles the growth of Europe genotyping market.

The Europe genotyping market, based on product and services, has been segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment held 37.5% market share in 2022, amassing US$ 2,319.62 million. It is projected to garner US$ 7,342.30 million by 2028 to expand at 21.2% CAGR during 2022–2028.

The Europe genotyping market, based on technology is segmented into Microarrays, Capillary Electrophoresis, Sequencing, Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-ToF) Mass Spectrometry, Polymerase Chain Reaction (PCR), and others. The Polymerase Chain Reaction (PCR) segment held 29.9% market share in 2022, amassing US$ 1,847.26 million. It is projected to garner US$ 5,905.29 million by 2028 to expand at 21.4% CAGR during 2022–2028.

The Europe genotyping market, based on application is segmented into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and others. The diagnostics and personalized medicine segment held 32.7% market share in 2022, amassing US$ 2,018.12 million. It is projected to garner US$ 6,282.14 million by 2028 to expand at 20.8% CAGR during 2022–2028.

The Europe genotyping market, based on end user is segmented into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and others. The diagnostic and research laboratories segment held 47.6% market share in 2022, amassing US$ 2,938.41 million. It is projected to garner US$ 9,276.68 million by 2028 to expand at 21.1% CAGR during 2022–2028.

Based on country, the Europe genotyping market is categorized into the UK, Germany, France, Italy, Spain, and the rest of Europe. Our regional analysis states that Germany captured 26.6% market share in 2022. It was assessed at US$ 1,644.88 million in 2022 and is likely to hit US$ 5,235.70 million by 2028, exhibiting a CAGR of 21.3% during the forecast period.

Key players dominating the Europe genotyping market are BioTek Instruments, Inc.; Eurofins Genomics; F. Hoffmann-La Roche Ltd.; Illumina, Inc.; Integrated DNA Technologies, Inc.; MERCK KGaA; QIAGEN; Thermo Fisher Scientific Inc; and TrimGen Corporation among others.

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Europe Genotyping Market – By Product and Services

1.3.2 Europe Genotyping Market – By Technology

1.3.3 Europe Genotyping Market – By Application

1.3.4 Europe Genotyping Market – By End User

1.3.5 Europe Genotyping Market – By Country

2. Europe Genotyping Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Europe Genotyping Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 Europe PEST Analysis

4.3 Experts Opinion

5. Europe Genotyping Market– Key Market Dynamics

5.1 Market Drivers

5.1.1 Use of Genotyping in Drug Development for Genetic and Rare Diseases

5.1.2 Technological Advancements and Rising R&D Investments in Pharmaceutical and Biotechnology

5.2 Market Restraints

5.2.1 High Cost of Equipment and Shortage of skilled Professionals required for Genotyping process

5.3 Market Opportunities

5.3.1 Wide Applications of Genotyping

5.4 Future Trends

5.4.1 Rising focus on Personalized Medicine

5.5 Impact analysis

6. Genotyping Market– Europe Analysis

6.1 Europe Genotyping Market Revenue Forecast and Analysis

7. Europe Genotyping Market– by Product and Services

7.1 Overview

7.2 Europe Genotyping Market, By Product and Services, 2022 & 2028 (%)

7.3 Reagents and Kits

7.3.1 Overview

7.3.2 Reagents and Kits: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

7.4 Genotyping Services

7.4.1 Overview

7.4.2 Genotyping Services: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

7.5 Bioinformatics

7.5.1 Overview

7.5.2 Bioinformatics: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

7.6 Instruments

7.6.1 Overview

7.6.2 Instruments: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

8. Europe Genotyping Market– by Technology

8.1 Overview

8.2 Europe Genotyping Market Share by Technology - 2022 & 2028 (%)

8.3 Polymerase Chain Reaction (PCR)

8.3.1 Overview

8.3.2 Polymerase Chain Reaction: Europe Genotyping Market Revenue and Forecast to 2028 (US$ Million)

8.4 Capillary Electrophoresis (CE)

8.4.1 Overview

8.4.2 Capillary Electrophoresis: Europe Genotyping Market Revenue and Forecast to 2028 (US$ Million)

8.5 Sequencing

8.5.1 Overview

8.5.2 Sequencing: Europe Genotyping Market Revenue and Forecast to 2028 (US$ Million)

8.6 Microarrays

8.6.1 Overview

8.6.2 Microarrays: Europe Genotyping Market Revenue and Forecast to 2028 (US$ Million)

8.7 Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof) Mass Spectrometry

8.7.1 Overview

8.7.2 Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof) Mass Spectrometry: Europe Genotyping Market Revenue and Forecast to 2028 (US$ Million)

8.8 Others

8.8.1 Overview

8.8.2 Others: Europe Genotyping Market Revenue and Forecast to 2028 (US$ Million)

9. Europe Genotyping Market–by Application

9.1 Overview

9.2 Europe Genotyping Market Share by Application - 2022 & 2028 (%)

9.3 Diagnostics and Personalized Medicine

9.3.1 Overview

9.3.2 Diagnostics and Personalized Medicine: Europe Genotyping Market Revenue and Forecast to 2028 (US$ Million)

9.4 Pharmacogenomics

9.4.1 Overview

9.4.2 Pharmacogenomics: Europe Genotyping Market Revenue and Forecast to 2028 (US$ Million)

9.5 Animal Genetics

9.5.1 Overview

9.5.2 Animal Genetics: Europe Genotyping Market Revenue and Forecast to 2028 (US$ Million)

9.6 Agricultural Biotechnology

9.6.1 Overview

9.6.2 Agricultural Biotechnology: Europe Genotyping Market Revenue and Forecast to 2028 (US$ Million)

9.7 Others

9.7.1 Overview

9.7.2 Others: Europe Genotyping Market Revenue and Forecast to 2028 (US$ Million)

10. Europe Genotyping Market– by End User

10.1 Overview

10.2 Europe Genotyping Market Share by End User- 2022 & 2028 (%)

10.3 Diagnostic and Research Laboratories

10.3.1 Overview

10.3.2 Diagnostic and Research Laboratories: Europe Genotyping Market Revenue and Forecast to 2028 (US$ Million)

10.4 Pharmaceutical and Biopharmaceutical Companies

10.4.1 Overview

10.4.2 Pharmaceutical and Biopharmaceutical Companies: Europe Genotyping Market Revenue and Forecast to 2028 (US$ Million)

10.5 Academic Institutes

10.5.1 Overview

10.5.2 Academic Institutes: Europe Genotyping Market Revenue and Forecast to 2028 (US$ Million)

10.6 Others

10.6.1 Overview

10.6.2 Others: Europe Genotyping Market Revenue and Forecast to 2028 (US$ Million)

11. Europe Genotyping Market– Country Analysis

11.1 Europe: Genotyping Market

11.1.1 Overview

11.1.3 Europe: Genotyping Market, by Country, 2021 & 2028 (%)

11.1.3.1 Germany: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.1.1 Overview

11.1.3.1.2 Germany: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.1.3 Germany: Genotyping Market, by Product and Services – Revenue and Forecast to 2028 (US$ Million)

11.1.3.1.4 Germany: Genotyping Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

11.1.3.1.5 Germany: Genotyping Market, by Application– Revenue and Forecast to 2028 (US$ Million)

11.1.3.1.6 Germany: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

11.1.3.2 France: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.2.1 Overview

11.1.3.2.2 France: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.2.3 France: Genotyping Market, by Product and Services – Revenue and Forecast to 2028 (US$ Million)

11.1.3.2.4 France: Genotyping Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

11.1.3.2.5 France: Genotyping Market, by Application– Revenue and Forecast to 2028 (US$ Million)

11.1.3.2.6 France: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

11.1.3.3 UK: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.3.1 Overview

11.1.3.3.2 UK: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.3.3 UK: Genotyping Market, by Product and Services – Revenue and Forecast to 2028 (US$ Million)

11.1.3.3.4 UK: Genotyping Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

11.1.3.3.5 UK: Genotyping Market, by Application– Revenue and Forecast to 2028 (US$ Million)

11.1.3.3.6 UK: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

11.1.3.4 Italy: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.4.1 Overview

11.1.3.4.2 Italy: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.4.3 Italy: Genotyping Market, by Product and Services – Revenue and Forecast to 2028 (US$ Million)

11.1.3.4.4 Italy: Genotyping Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

11.1.3.4.5 Italy: Genotyping Market, by Application– Revenue and Forecast to 2028 (US$ Million)

11.1.3.4.6 Italy: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

11.1.3.5 Spain: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.5.1 Overview

11.1.3.5.2 Spain: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.5.3 Spain: Genotyping Market, by Product and Services – Revenue and Forecast to 2028 (US$ Million)

11.1.3.5.4 Spain: Genotyping Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

11.1.3.5.5 Spain: Genotyping Market, by Application– Revenue and Forecast to 2028 (US$ Million)

11.1.3.5.6 Spain: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

11.1.3.6 Rest of Europe: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.6.1 Overview

11.1.3.6.2 Rest of Europe: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.6.3 Rest of Europe: Genotyping Market, by Product and Services – Revenue and Forecast to 2028 (US$ Million)

11.1.3.6.4 Rest of Europe: Genotyping Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

11.1.3.6.5 Rest of Europe: Genotyping Market, by Application– Revenue and Forecast to 2028 (US$ Million)

11.1.3.6.6 Rest of Europe: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12. Europe Genotyping Market Industry Landscape

12.1 Overview

12.2 Organic Developments

12.2.1 Overview

12.3 Inorganic Developments

12.3.1 Overview

13. Company Profiles

13.1 F. HOFFMANN-LA ROCHE LTD.

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 INTEGRATED DNA TECHNOLOGIES, INC. (DANAHER)

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 QIAGEN

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 MERCK KGaA

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 EUROFINS GENOMICS

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 THERMO FISHER SCIENTIFIC INC.

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 BioTek Instruments, Inc.

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 TRIMGEN CORPORATION

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Financial Overview

13.8.4 SWOT Analysis

13.8.5 Key Developments

13.9 Illumina, Inc.

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

LIST OF TABLES.

Table 1.             The pharmaceutical company partnered with genomic health databases

Table 2.             Europe Genotyping Market –Revenue and Forecast to 2028 (US$ Million)

Table 3.             Germany: Genotyping Market, by Product and Services – Revenue and Forecast to 2028 (US$ Million)

Table 4.             Germany: Genotyping Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 5.             Germany: Genotyping Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 6.             Germany: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 7.             France: Genotyping Market, by Product and Services – Revenue and Forecast to 2028 (US$ Million)

Table 8.             France: Genotyping Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 9.             France: Genotyping Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 10.          France: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 11.          UK: Genotyping Market, by Product and Services – Revenue and Forecast to 2028 (US$ Million)

Table 12.          UK: Genotyping Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 13.          UK: Genotyping Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 14.          UK: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 15.          Italy: Genotyping Market, by Product and Services – Revenue and Forecast to 2028 (US$ Million)

Table 16.          Italy: Genotyping Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 17.          Italy: Genotyping Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 18.          Italy: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 19.          Spain: Genotyping Market, by Product and Services – Revenue and Forecast to 2028 (US$ Million)

Table 20.          Spain: Genotyping Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 21.          Spain: Genotyping Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 22.          Spain: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 23.          Rest of Europe: Genotyping Market, by Product and Services – Revenue and Forecast to 2028 (US$ Million)

Table 24.          Rest of Europe: Genotyping Market, by Technology– Revenue and Forecast to 2028 (US$ Million)

Table 25.          Rest of Europe: Genotyping Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 26.          Rest of Europe: Genotyping Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 27.          Organic Developments Done By Companies

Table 28.          Inorganic Developments Done By Companies

Table 29.          Glossary of Terms

LIST OF FIGURES.

Figure 1.           Europe Genotyping Market Segmentation

Figure 2.           Europe Genotyping Market – By Country

Figure 3.           Europe Genotyping Market Overview

Figure 4.           Reagents and Kits Held Largest Share by Product and Services of Europe Genotyping Market

Figure 5.           UK to Show Significant Growth During Forecast Period

Figure 6.           Europe: PEST Analysis

Figure 7.           Experts Opinion

Figure 8.           Europe Genotyping Market Impact Analysis of Driver and Restraints

Figure 9.           Europe Genotyping Market– Revenue Forecast and Analysis – 2022 - 2028

Figure 10.        Europe Genotyping Market, by Product and Services, 2022 & 2028 (%)

Figure 11.        Reagents and Kits: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 12.        Genotyping Services: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 13.        Bioinformatics: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 14.        Instruments: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 15.        Europe Genotyping Market Share by Technology - 2022 & 2028 (%)

Figure 16.        Polymerase Chain Reaction: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 17.        Capillary Electrophoresis: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 18.        Sequencing: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 19.        Microarrays: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 20.        Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof) Mass Spectrometry: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 21.        Others: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 22.        Europe Genotyping Market Share by Application - 2022 & 2028 (%)

Figure 23.        Diagnostics and Personalized Medicine: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 24.        Pharmacogenomics: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 25.        Animal Genetics: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 26.        Agricultural Biotechnology: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 27.        Others: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 28.        Europe Genotyping Market Share by End User- 2022 & 2028 (%)

Figure 29.        Diagnostic and Research Laboratories: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 30.        Pharmaceutical and Biopharmaceutical Companies: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 31.        Academic Institutes: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 32.        Others: Europe Genotyping Market Revenue and Forecasts to 2028 (US$ Million)

Figure 33.        Europe: Genotyping Market, by Key Country – Revenue (2022) (US$ Million)

Figure 34.        Europe: Genotyping Market, by Country, 2021 & 2028 (%)

Figure 35.        Germany: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

Figure 36.        France: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

Figure 37.        UK: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

Figure 38.        Italy: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

Figure 39.        Spain: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

Figure 40.        Rest of Europe: Genotyping Market – Revenue and Forecast to 2028 (US$ Million)

The List of Companies - Europe Genotyping Market

● BioTek Instruments, Inc.

● Eurofins Genomics

● F. Hoffmann-La Roche Ltd.

● Illumina, Inc.

● Integrated DNA Technologies, Inc.

● MERCK KGaA

● QIAGEN

● Thermo Fisher Scientific Inc

● TrimGen Corporation

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe Genotyping Market.

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the Europe Genotyping Market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Genotyping Market, as well as those hindering it

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

TOP